Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

NextCure Inc

NXTC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$8.21

▼ -0.85%

Market Cap $37.58M · Vol 44.11K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$37.58M

Micro Cap

Div Yield

N/A

EPS Growth

+60.38%

YoY

RSI (14)

71.82

Momentum

Beta

1.53

vs Market

52W High

$15.61

47.41% below

52W Low

$1.55

429.68% above

Volume

44.11K

Avg 471.52K

P/B

1.42

Price-to-book

ROE

N/A

Return on equity

Free Float

91.36%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, NextCure Inc (NXTC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NXTC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+40.58%

+24.77%

-19.90%

-37.33%

YTD

-42.14%

+59.42%

-59.75%

-90.51%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-55,844,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-85.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.42
P/FCF	N/A
EPS Growth	+60.38%
Outstanding Shares	4.58M

Technical Indicators

50-Day SMA	$3.84
200-Day SMA	$9.36
RSI (14)	71.82
Beta	1.53
52-Week High	$15.61
52-Week Low	$1.55

Volume Today	44.11K
Avg Daily Volume (30D)	471.52K
Relative Volume	0.09x
Volatility (10D)	165.43
Volatility (30D)	352.08
Free Float	91.36%

Analyst Consensus

BUY

Current Price $8.21

Mean Target $20.00

52W Low$1.55 52W High$15.61

Current

Target

$1.55 $15.61

Current Analyst target

+143.61% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00BTH5162

ISINUS65343E2072

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.